IL Chicago의 삼중음성 유방암 임상 시험
삼중음성 유방암 관련 연구 16개가 Chicago 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
피험자 모집 중1상
- University of Chicago Hospital, Chicago
PRE-ISPY Phase I/II Oncology Platform Program
피험자 모집 중1/2상
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
피험자 모집 중3상
- University of Illinois Cancer Center ( Site 0044), Chicago
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
피험자 모집 중1상
- Northwestern University Feinberg School of Medicine, Chicago
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
피험자 모집 중3상
- Northwestern Medicine, Chicago
- Rush University Medical Center, Chicago
- University of Chicago Medical Center, Chicago
SMP-3124LP in Adults With Advanced Solid Tumors
피험자 모집 중1/2상
- Northwestern Medicine Cancer Center, Chicago
- The University of Chicago, Chicago
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
피험자 모집 중2/3상
- Local Institution - 0280, Chicago
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
피험자 모집 중1/2상
- Northwestern University, Chicago
A Study of LY4175408 in Participants With Advanced Cancer
피험자 모집 중1상
- The University of Chicago Medical Center (UCMC), Chicago
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
피험자 모집 중1상
- University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
- University of Chicago Medical Center /ID# 276271, Chicago
Study of XB010 in Subjects With Solid Tumors
피험자 모집 중1상
- University of Chicago Medical Center, Chicago
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
피험자 모집 중1/2상
- Northwestern Memorial Hospital, Chicago
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
피험자 모집 중2상
- University of Chicago, Chicago
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
피험자 모집 중2상
- University of Chicago Medical Center, Chicago
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
피험자 모집 중1상
- UChicago Medicine Comprehensive Cancer Center, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
피험자 모집 중1상
- University of Chicago, Chicago
다른 도시의 삼중음성 유방암 시험
- Houston, TX연구 42개
- New York City, NY연구 31개
- Nashville, TN연구 28개
- Los Angeles, CA연구 27개
- Boston, MA연구 26개
- San Antonio, TX연구 23개
- St. Louis, MO연구 21개
- Arlington, VA연구 20개
- Atlanta, GA연구 20개
- Dallas, TX연구 18개
- Columbus, OH연구 16개
- Grand Rapids, MI연구 15개
Chicago의 다른 연구
- 비소세포폐암연구 61개
- 유방암연구 59개
- 암 (전체)연구 51개
- 전이성 암연구 45개
- 전립선암연구 45개
- 폐암연구 41개
- 비만연구 41개
- 난소암연구 36개
- 대장직장암연구 34개
- 뇌졸중연구 34개
- 심부전연구 31개
- 과체중연구 29개
ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.